FindTrial
Sign In

Evaluation of toxicity and response to stereotactic body radiotherapy in unresectable and borderline resectable pancreatic cancer.

Evaluation of acute toxicity and response to stereotactic body radiotherapy in unresectable and borderline resectable pancreatic cancer: a prospective single arm study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080026
Enrollment
21
Registered
2025-02-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified

Interventions

Intervention1: Stereotactic body radiation therapy. For 5 days on each patient: No comparator agent. Effects and response will be studied

Sponsors

AIIMS Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ECOG PS-O-2 Patients with histologically proven pancreatic cancer Unresectable or borderline resectable defined as per NCCN clinical practice guidelines in Oncology.

Exclusion criteria

Exclusion criteria: ECOG PS >2 Patients who did not give consent for study Patients with associated comorbidities Patients who previously received radiation

Design outcomes

Primary

MeasureTime frame
To evaluate the acute toxicity of SBRTTimepoint: 14DAYS—

Secondary

MeasureTime frame
To assess for tumor response. To evaluate the conversion of inoperable to operable carcinoma pancreasTimepoint: 1.5 month—

Countries

India

Contacts

Public ContactDr. Swrangsri Mashahary

AIIMS, BHUBANESWAR

radonc_dilip@aiimsbhubaneswar.edu.in9438884060

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026